)
Edge28 Aug 2026
Bigger, Sharper, IMAX: A Blockbuster Business
How IMAX turned an unscalable, large-screen format into the center of blockbuster filmmaking through cameras, projection, and remastering technology.
Curasight
Curasight (CURAS) investor relations material
Curasight Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary31 Aug, 2026
Executive summary
Focus on developing a uPAR-targeted theranostic platform for diagnosis and treatment of aggressive solid tumors, including glioblastoma, NSCLC, and others, with both diagnostic (uTRACE®) and therapeutic (uTREAT®) programs in clinical and preclinical trials.
Achieved key clinical progress with encouraging preliminary Phase 1 data for uTREAT® in glioblastoma, marking a significant milestone for the platform.
Recent internal ownership restructuring consolidated co-founders' holdings under Curacap II ApS, now holding 27.69% of shares, without affecting operations or strategy.
Strengthened financial position through a DKK 20 million directed share issue and extension of a DKK 35 million convertible loan to mid-2027, supporting ongoing clinical programs.
Updated clinical timelines: topline Phase I uTREAT® in glioblastoma and Phase II uTRACE® in prostate cancer expected H1 2027.
Financial highlights
H1 2026 gross loss: KDKK -22,875 (vs. KDKK -22,399 year-over-year); operating loss: KDKK -26,771 (vs. KDKK -25,220); loss before tax: KDKK -29,505 (vs. KDKK -27,158); net loss: KDKK -26,755 (vs. KDKK -24,408).
Q2 2026 gross loss: KDKK -9,797 (vs. KDKK -17,700); operating loss: KDKK -11,493 (vs. KDKK -19,011); loss before tax: KDKK -12,800 (vs. KDKK -20,579); net loss: KDKK -11,425 (vs. KDKK -19,204).
Total assets: KDKK 56,081 (vs. KDKK 44,783); equity ratio: 27.1% (vs. 67.6%); EPS: DKK -0.24 (vs. DKK -0.43).
Cash in hand as of June 30, 2026: KDKK 41,026 (vs. KDKK 29,449 year-over-year).
Short-term debt: KDKK 40,868, mainly from a drawn credit facility.
Outlook and guidance
Topline results for Phase I uTREAT® in glioblastoma and Phase II uTRACE® in prostate cancer expected H1 2027, with timelines reflecting patient enrollment uncertainties.
Protocol amendment in Phase I uTREAT® trial aims to optimize study design and broaden data for next phase.
Regulatory tailwind anticipated for glioblastoma program.
Continued disciplined execution and robust clinical evidence generation are strategic priorities.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Curasight
- uTREAT trials in brain cancer begin 2025, with strong funding and major partnership milestones ahead.CURAS
Status update - Losses widened in Q1 2026, but clinical and financial progress set up key 2026 milestones.CURASQ1 2026
- Losses increased but cash and equity improved, with major clinical and financing milestones achieved.CURASQ4 2025
- Advanced clinical pipeline and strong cash position despite higher losses year-over-year.CURASQ3 2025
- Financials strengthened and clinical trials advanced in prostate and brain cancer.CURASQ2 2025
- Curasight achieved major clinical and financing milestones, strengthening its position in radiopharma.CURASQ3 2024
- Losses widened but new funding and clinical milestones support growth into 2025.CURASQ2 2024
- DKK 100 million rights issue to fund pivotal cancer trials, with 47% secured by commitments.CURASInvestor update
- Rights issue targets DKK 100 million to fund key cancer platform trials and extend cash runway.CURASInvestor update
Next Curasight earnings date
Q3 202626 Nov, 2026
Curasight
Next Curasight earnings date
Q3 202626 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage